Rajanandh Muhasaparur Ganesan, Nageswari Arcot D, Prathiksha Giridharan
Department of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
Department of Pulmonary Medicine, SRM Medical College Hospital and Research Center, SRM University, Kattankulathur, Tamil Nadu, India.
J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):142-6. doi: 10.4103/0976-500X.162022.
To assess the pulmonary function and quality of life in asthma patients receiving vitamin D3 supplementation with inhaled budesonide and formoterol.
This was a double blinded, randomized, comparative study. Patients were recruited as per the study criteria and randomized into two groups: usual care group (n = 69) patients received budesonide (800 μg) with formoterol (24 μg) and intervention care group (n = 72) patients received vitamin D3 (1000 IU) supplementation along with budesonide (800 μg) plus formoterol (24 μg) for a period of 6 months.
A total of 140 patients completed the study. Significant within-group improvement and non-significant between-group improvement is observed with respect to FEV1. In terms of health-related quality of life, within-group comparison revealed a significant (P < 0.05) improvement in all the domains of SGRQ. However, between-group comparisons showed statistically significant (P < 0.05) improvement in symptom, impact and total scores.
On the basis of our findings, we conclude that supplementation of vitamin D3 is effective in improving the quality of life rather than pulmonary function in severe asthmatics. However, further studies are warranted to substantiate the present findings.
评估接受维生素D3补充剂联合吸入布地奈德和福莫特罗治疗的哮喘患者的肺功能和生活质量。
这是一项双盲、随机、对照研究。根据研究标准招募患者,并随机分为两组:常规护理组(n = 69)患者接受布地奈德(800μg)联合福莫特罗(24μg)治疗,干预护理组(n = 72)患者在接受布地奈德(800μg)联合福莫特罗(24μg)治疗的同时补充维生素D3(1000IU),为期6个月。
共有140名患者完成了研究。观察到FEV1在组内有显著改善,而组间改善不显著。在健康相关生活质量方面,组内比较显示SGRQ所有领域均有显著(P < 0.05)改善。然而,组间比较显示症状、影响和总分有统计学显著(P < 0.05)改善。
根据我们的研究结果,我们得出结论,补充维生素D3对改善重度哮喘患者的生活质量有效,而非肺功能。然而,需要进一步研究来证实目前的研究结果。